Compare American Financial Group Inc (AFG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Moderna, Inc. — how do they compare? American Financial Group Inc trades at $144.72 (market cap $11.97B), while Moderna, Inc. trades at $63.51 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 2× American Financial Group Inc's market cap, and American Financial Group Inc pays a 2.44% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AFG | MRNA | |
|---|---|---|
Market Cap | $11.97B | $24.18B |
Sector | Financials | Health |
52-Week High | $148.71 | $81.80 |
52-Week Low | $124.18 | $22.36 |
Enterprise Value | $12.35B | $20.33B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.82, up 0.66% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 is projected at $8.2 billion with an 11.66% margin. Analysts have a consensus price target of $160.67, with 41% recommending buy.
AFG presents a positive outlook with solid earnings beats and a shareholder-friendly dividend policy, but faces risks from competitive pressures and potential market volatility. The stock's current valuation at a P/E of 12.62 offers room for growth relative to historical averages, supported by institutional interest and consistent cash flow generation.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
